Edesa Biotech is trading 8.29% up at $5.88, with the after-hours gain appearing driven by completed preparations and site activation for the Phase 2 EB06 vitiligo study.
- Fiscal third-quarter results released August 13, 2026 showed a $5.4 million net loss, or $0.60 per share, missing the $0.58 consensus estimate.
- Research spending increased sharply; regular-session shares closed at $5.43, while the broader market also rose.